Following an inspection from the US medicines regulator, a manufacturing site run by Indian active pharmaceutical ingredient (API) specialist Aparna Pharmaceuticals has received a VAI classification.
The result indicates that FDA investigators discovered “objectionable conditions” during the inspection, but that these are below the threshold of severity for enforcement action to take place.
Based in Hyderabad, Aparna manufactures advanced drug intermediates and APIs, and aims to be the preferred partner for pharmaceutical companies worldwide, by assuring “the highest benchmarks of quality, dependability, innovation, and regulatory compliance.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze